Axcella’s stock is up 10% after sharing new data for its NASH treatment

Shares of Axcella Therapeutics Inc. AXLA, +7.24% gained 10.9% in premarket trading on Thursday after the biotech said its experimental treatment for nonalcoholic steatohepatitis (NASH) showed statistically significant improvement in liver stiffness at 24 weeks. The Phase 2b trial is ongoing. The company expects to have topline data from the 48-week mark by the first half of 2024. Axcella’s stock is down 17.2% this year, while the broader S&P 500 SPX, -1.66% has declined 21.9%.

Murrey Math Lines 12.04.2024 (Brent, S&P 500)

Brent Brent quotes are above the 200-day Moving Average on D1, indicating a prevailing uptrend. The RSI has broken the support line, exiting the overbought

Technical Analysis & Forecast 12.04.2024

EURUSD, “Euro vs US Dollar” The EURUSD pair continues developing a consolidation range. By now, a decline wave structure has been completed at 1.0700 alongside

Ichimoku Cloud Analysis 12.04.2024 (EURUSD, XAUUSD, NZDUSD)

EURUSD, “Euro vs US Dollar” EURUSD has secured under the support level. The instrument is going below the Ichimoku Cloud, revealing a downtrend. A test

Searching for the right forex broker is no easy task, but have no fear! Brokerswatch.com has made it very simple. Find the right brokers based on the criteria most important to you and compare them side by side for easier selection

Brokers By Regulator

Forex Brokers List

Trading Tools

Risk Warning: FX trading is high risk and may not be suitable for all investors. Leverage will create additional risks and loss. Before trading, please carefully consider your investment goals, experience and risk tolerance levels. Loss of part or all of your initial investment is possible; therefore do not invest money that you cannot afford to lose. It is advised to educate yourself about FX trading before you trade real money. Disclaimer: All data and information on this Website are provided “as is” and to be used only for information purposes. Information is not intended for trading or trading recommendations. The operators of this website shall not be liable for any loss incurred by you as a result of reliance on the information contained in the Website.